GUIDELINESDIAGNOSISTREATMENTLUNGCANCERContents1. Overview2. Risk factors of prostate cancer2.1 Age and genetic factors2.2 Exogenous factors3. Pathological classification and grading system4. Diagnostic evaluation4.1 Monitoring and screening for population with high-risk prostate cancer4.2 Genetic testing4.3 ...
3,4 While androgen-deprivation therapy (ADT), which reduces circulating testosterone levels, has been the cornerstone of treatment, single-agent ADT alone often fails to sustain long-term efficacy, as prostate cancer cells develop adaptive resistance to testosterone suppression. In recent years, the ...
Additional research is indicated to optimally inform clinical guidelines addressing screening, prevention, and treatment of bone health in those affected by cancer and cancer therapies.Abbreviations:Abbreviations: ADT androgen deprivation therapy AI aromatase inhibitor BCa breast cancer BMD bone mineral ...
Genetic testing, to identify pathogenic or likely pathogenic variants in prostate cancer, is valuable in guiding treatment decisions for men with prostate cancer and to inform cancer prevention and early detection options for their immediate blood relatives. There are various guidelines and consensus stat...
Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 17-05229-EF-3. 25. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer. 2010;126(10):2387-2393.PubMed...
Noteworthy prostate cancer-related research from 2018 span a wide range, from diagnostic advances to breakthroughs in treatment of metastatic and non-metastatic disease. To recap the year in prostate cancer research, Urology Times asked Christopher P. Filson, MD, MS, Adam Kibel, MD, and Stacy Lo...
Prostate cancer. Accessed December 1, 2023. https://uroweb.org/guidelines/prostate-cancer 45. Narayan VM. A critical appraisal of biomarkers in prostate cancer. World J Urol. 2020;38(3):547-554. doi:10.1007/s00345-019-02759-xPubMedGoogle ScholarCrossref 46. Nordström T, ...
Prostate Cancer early detection (version 2.2018) [37]National Comprehensive Cancer Network, 2018YesMen opting to participate in an early detection program after receiving the appropriate counseling on benefits and harms The guidelines for when to start and stop screening, at what intervals to conduct ...
Nearly one-third of patients with prostate cancer (PCa) experience biochemical recurrence (BCR) after primary definitive treatment. BCR increases the risk of distant metastasis and mortality in patients with prognostically unfavorable features. These patients are best managed with a tailored treatment str...
M. et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat. Rev. Urol. 13, 151–167 (2016). Article CAS PubMed Google Scholar Barrett, T. & Haider, M. A. The emerging role of MRI in prostate cancer active surveillance and ongoing challenges. AJR...